AnaptysBio, Inc. (ANAB) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $1.68B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Daniel Faga |
| IPO Date | 2017-01-26 | CAGR | 36.75% |
| Employees | 104 | Website | www.anaptysbio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 1.96% | Total Yield | 1.96% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $278.34M | P/E | -52.59 | Forward P/E | 10.85 | PEG | — |
| P/S | 14.4 | P/B | 174.96 | P/CF | 498.03 | P/FCF | 760.23 |
| Sales | $232.39M | Sales 1Y | 107.73% | Sales 3Y | 2073.68% | Sales 5Y | 226.17% |
| EPS | $-1.08 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | -76.39% | EPS QoQ | -216.46% | Sales QoQ Avg | 47.11% | EPS QoQ Avg | -36.68% |
| Gross Margin | 116.42% | Operating Margin | 17.56% | Profit Margin | -11.53% | ROCE | 14.17% |
| ROA | -8% | ROE | 443% | Altman Z Score | 1.89 | Piotroski Score | 5 |
| Current Ratio | 7.58 | Quick Ratio | 7.58 | Cash Ratio | 5.96 | Op. CF Ratio | -0.62 |
| Debt/Equity | 21.76 | Debt/Assets | 0.84 | Lt Debt/Equity | 21.59 | Lt Debt/Cap. | 0.95 |
| Intrst Cov. | 0.49 | Inventory Turnover | — | Asset Turnover | 0.7 | Receivables Turnover | 9.03 |
| Enterprise Value | $278.34M | P/E Ratio | -52.59 |
| Forward P/E | 10.85 | PEG Ratio | — |
| P/S Ratio | 14.4 | P/B Ratio | 174.96 |
| P/CF Ratio | 498.03 | P/FCF Ratio | 760.23 |
| EPS | $-1.08 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 107.73% | Gross Margin | 1.16% |
| Operating Margin | 0.18% | Profit Margin | -0.12% |
| ROE | 4.43% | ROA | -0.08% |
| ROCE | 0.14% | Current Ratio | 7.58 |
| Quick Ratio | 7.58 | Cash Ratio | 5.96 |
| Debt/Equity | 21.76 | Interest Coverage | 0.49 |
| Altman Z Score | 1.89 | Piotroski Score | 5 |
AnaptysBio, Inc. (ANAB) valuation & financials
AnaptysBio, Inc. (ANAB) has a market capitalization of $1.68B and trades at a price-to-earnings ratio of -52.6. It operates in the Healthcare sector (Biotechnology).
AnaptysBio, Inc.'s revenue grew +107.7% over the last year.
AnaptysBio, Inc.'s next earnings report is scheduled for November 10, 2026; analysts estimate EPS of $-0.06. Check the earnings calendar to see all companies reporting this week.
AnaptysBio, Inc. (ANAB) — frequently asked questions
When does AnaptysBio, Inc. (ANAB) report earnings next?
AnaptysBio, Inc. is expected to report earnings on November 10, 2026. Analysts estimate EPS of $-0.06.
What is AnaptysBio, Inc.'s market cap?
AnaptysBio, Inc. (ANAB) has a market capitalization of $1.68B.
What is ANAB's P/E ratio?
AnaptysBio, Inc. trades at a price-to-earnings ratio of -52.6, with trailing twelve-month EPS of $-1.08.
How fast is AnaptysBio, Inc. growing?
AnaptysBio, Inc.'s revenue grew +107.7% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)